Fragmin® 5000 IU

DRUG2 trials

Sponsors

Institut Gustave Roussy, Anthos Therapeutics Inc.

Conditions

Thromboprophylaxis in good and intermediate prognosis advanced germ cell tumorsvenous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer

Phase 2

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Active, not recruitingCTIS2024-513992-42-00

Anthos Therapeutics Inc.venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer

Start: 2022-09-13Target: 677Updated: 2025-12-15

Phase 3

Thromboprophylaxis in good and intermediate prognosis advanced germ cell tumors (GIG-T)

RecruitingCTIS2022-502426-41-00

Institut Gustave RoussyThromboprophylaxis in good and intermediate prognosis advanced germ cell tumors

Start: 2023-10-17Target: 387Updated: 2026-01-13